Cargando…

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

BACKGROUND: Multiple myeloma (MM) is a complex heterogeneous disease. Various risk stratification models have been recommended including cytogenetic and FISH analysis to identify high-risk patients who may benefit from novel treatments, but such facilities are not widely available. The International...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ting, Kay Reen, Henry, Michael, Meiller, Justine, Larkin, Annemarie, Clynes, Martin, Meleady, Paula, Bazou, Despina, Dowling, Paul, O'Gorman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502697/ https://www.ncbi.nlm.nih.gov/pubmed/28725572 http://dx.doi.org/10.1016/j.bbacli.2017.05.003

Ejemplares similares

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
por: Dowling, Paul, et al.
Publicado: (2014)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

Bone Disease in Multiple Myeloma: Pathophysiology and Management
por: Hameed, Abdul, et al.
Publicado: (2014)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020)

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
por: Dowling, Paul, et al.
Publicado: (2021)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients
por: Dowling, Paul, et al.
Publicado: (2014)

Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report
por: Waterhouse, Deirdre F, et al.
Publicado: (2009)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Yeast Mannan-Rich Fraction Modulates Endogenous Reactive Oxygen Species Generation and Antibiotic Sensitivity in Resistant E. coli
por: Smith, Helen, et al.
Publicado: (2022)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells
por: Lee, Young Shin, et al.
Publicado: (2018)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry
por: Holland, Ashling, et al.
Publicado: (2014)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Quantitative label-free mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue representing the invasive cutaneous malignant melanoma proteome
por: Dowling, Paul, et al.
Publicado: (2016)

Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems
por: Kulkarni, Anushka, et al.
Publicado: (2023)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
por: Chim, Chor Sang, et al.
Publicado: (2012)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
por: Cho, Hee-Jeong, et al.
Publicado: (2018)

PB1953: ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS.
por: Eleonora, M., et al.
Publicado: (2022)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tp4uos8bnqiprlfjso5hklibn2